AC Immune (ACIU) Change in Receivables (2017 - 2025)
AC Immune (ACIU) posted quarterly Change in Receivables of $751953.0 for Q4 2025, down 97.32% year-over-year from $28.1 million in Q4 2024, and up 1974.17% quarter-over-quarter from $36253.2 in Q3 2025.
AC Immune (ACIU) Change in Receivables (2017 - 2025) Analysis & Trends
AC Immune (ACIU) has reported Change in Receivables for 8 consecutive years, with $751953.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Receivables fell 97.32% year-over-year to $751953.0; the TTM figure through Dec 2025 stood at $326140.6 (down 98.04% YoY), while the FY2025 annual figure was $217103.1, down 98.71% from the prior year.
- Change in Receivables advanced to $751953.0 in Q4 2025 per ACIU's latest filing, from $36253.2 in the prior quarter.
- Across five years, Change in Receivables topped out at $28.1 million in Q4 2024 and bottomed at -$28.4 million in Q3 2024.
- Historically, Change in Receivables has averaged $29721.1 across 5 years, with a median of $36253.2 in 2025.
- On a YoY basis, Change in Receivables climbed as much as 7713.21% in 2024 and fell as far as 24248.75% in 2024.
- AC Immune's Change in Receivables stood at $107471.4 in 2021, then plunged by 166.66% to -$71642.2 in 2022, then slumped by 23167.1% to -$16.7 million in 2023, then jumped by 268.46% to $28.1 million in 2024, then sank by 97.32% to $751953.0 in 2025.
- Business Quant data shows ACIU's Change in Receivables at $751953.0 in Q4 2025, $36253.2 in Q3 2025, and $485571.9 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 751,953.04 |
| Dec 31, 2025 | 751,953.04 |
| Sep 30, 2025 | 36,253.18 |
| Sep 30, 2025 | 36,253.18 |
| Jun 30, 2025 | 485,571.87 |
| Jun 30, 2025 | 485,571.87 |
| Mar 31, 2025 | -947,637.46 |
| Mar 31, 2025 | -947,637.46 |
| Dec 31, 2024 | 28.08 Mn |
| Dec 31, 2024 | 28.08 Mn |
| Sep 30, 2024 | -28.39 Mn |
| Sep 30, 2024 | -28.39 Mn |
| Mar 31, 2024 | 16.96 Mn |
| Mar 31, 2024 | 16.96 Mn |
| Dec 31, 2023 | -16.67 Mn |
| Dec 31, 2023 | -16.67 Mn |
| Sep 30, 2023 | -116,611.71 |
| Sep 30, 2023 | -116,611.71 |
| Jun 30, 2023 | 328,091.79 |
| Jun 30, 2023 | 328,091.79 |